| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Hirudonucleodisulfide B exhibits moderate antihypoxic activity, meaning it can help protect against oxygen deprivation. As a heterocyclic compound found in Whitmania pigra, it may contribute to the therapeutic properties of this leech species used in traditional medicine. It also exhibits antimicrobial activity.
|
|---|---|
| ln Vitro |
In vitro, Hirudonucleodisulfide B shows moderate antihypoxic activity. It exhibits antimicrobial activity. Specific in vitro data regarding potency and mechanisms are limited in the available literature.
|
| ln Vivo |
In vivo activity data for Hirudonucleodisulfide B are limited. The compound shows moderately anti-anoxic activity. As a component of Whitmania pigra used in traditional medicine, it may contribute to therapeutic effects. Specific animal model studies have not been detailed.
|
| Enzyme Assay |
Specific protocols for enzyme or receptor binding assays have not been established for Hirudonucleodisulfide B. Antihypoxic activity can be assessed using biochemical assays that measure oxygen consumption or cellular survival under hypoxic conditions. Antimicrobial activity is evaluated using standard MIC assays.
|
| Cell Assay |
Cell-based assays for Hirudonucleodisulfide B may include evaluating its protective effects in cells exposed to hypoxic conditions. Antimicrobial activity can be assessed in bacterial cultures. Cell viability is measured using standard assays such as MTT.
|
| Animal Protocol |
In vivo animal protocols for Hirudonucleodisulfide B have not been established. For related antihypoxic compounds, standard models involve administering the compound to animals and measuring survival under hypoxic conditions. Specific protocols for this compound are not documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Hirudonucleodisulfide B are not extensively reported. The compound has a molecular weight of 326.35 and a molecular formula of C11H10N4O4S2. Information concerning product stability, particularly in solution, has rarely been reported. Storage follows standard conditions for natural products.
|
| Toxicity/Toxicokinetics |
Toxicological data for Hirudonucleodisulfide B are limited. As a research-use-only compound, it has not undergone formal safety assessment. The compound is handled with standard laboratory precautions.
|
| References | |
| Additional Infomation |
Hirudonucleodisulfide B is a research-use-only compound. It is a heterocyclic compound found in Whitmania pigra. It is a bioactive epidithiodiketopiperazine metabolite. It exhibits moderate antihypoxic activity and antimicrobial activity. It is used in natural product and traditional medicine research.
|
| Molecular Formula |
C11H10N4O4S2
|
|---|---|
| Molecular Weight |
326.352
|
| Exact Mass |
326.014
|
| CAS # |
1072789-38-8
|
| PubChem CID |
42614050
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.03±0.1 g/cm3(Predicted)
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CSc1c(sc2nc3[nH]c(=O)[nH]c(=O)c3nc12)C(O)CO
|
| InChi Key |
LNVKHOHWZGZHHS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H10N4O4S2/c1-20-7-4-10(21-6(7)3(17)2-16)13-8-5(12-4)9(18)15-11(19)14-8/h3,16-17H,2H2,1H3,(H2,13,14,15,18,19)
|
| Chemical Name |
7-(1,2-dihydroxyethyl)-6-methylsulfanyl-1H-thieno[3,2-g]pteridine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0642 mL | 15.3210 mL | 30.6419 mL | |
| 5 mM | 0.6128 mL | 3.0642 mL | 6.1284 mL | |
| 10 mM | 0.3064 mL | 1.5321 mL | 3.0642 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
